

New TB Medicines Dashboard

Guidance, Policy, and Procurement Information All in One Place



**World Health
Organization**



The Global Fund
To Fight AIDS, Tuberculosis and Malaria

USAID

Dr Brenda Waning
Chief, Stop TB Partnership's Global Drug Facility
Geneva, Switzerland
30 January, 2019
brendaw@stoptb.org

WHAT IS THE TB MEDICINES DASHBOARD? WHAT DOES IT INCLUDE?

- **Visualization tool** that measures policy and institutional coherence on selection, quality assurance, procurement, and use of TB medicines.
- Organizes, stores, and displays TB medicines information from **13 different sources** in one easy-to-access place. Specific content includes:
 - WHO Guidelines for Treatment and Prevention of TB
 - WHO Model Essential Medicine Lists (EMLs), including submissions
 - WHO Prequalification of Medicines List, and Expression of Interest
 - Global Fund Expert Review Panel List of Medicines, including submissions
 - Stop TB/GDF TB Medicines Catalog

HOW DOES THE DASHBOARD WORK?

- Developed and updated by the Stop TB Partnership's Global Drug Facility, in close collaboration with the World Health Organization, the Global Fund, and USAID
- The dashboard has **3 views: drug-resistant TB, drug-sensitive TB, & latent TB infection**
- Each view contains a list of medicines and its current status across the various guidance documents included in the dashboard.
- Click or hover over any dot to link to the primary data source, when applicable.

TB MEDICINES DASHBOARD: DR-TB VIEW

WHO Guidelines (DR-TB '16)

WHO Guidelines (DR-TB '18 - Communication)

EML submitted

EML (2017)

WHO PQEOI (2018)

WHO PQ submitted

WHO PQ listed

Global Fund ERP EOI (Aug 2018)

Global Fund ERP approved

GDF Catalog



WHERE CAN I FIND THE TB MEDICINES DASHBOARD?

- Currently on STBP website: www.stoptb.org/gdf/medicinesdashboard
- Soon to be Added to WHO website
- Interactive, “live” version
- Downloadable pdf versions

HOW WILL THE TB MEDICINES DASHBOARD HELP?


- **Identify areas of divergence** across contributing institutions and provide a roadmap to guide actions toward improved alignment and efficiency;
- Track progress on development and quality assurance of new medicines and formulations to **expedite new product introduction and scale-up**;
- **Send clear, consistent signals to suppliers** on the gaps in medicines and formulations that are not yet developed, as well as the medicines and formulations no longer needed;
- **Support market consolidation** and other market-shaping activities;
- **Facilitate benchmarking and revision of national tools:** guidelines, EMLs, and procurement lists against global guidance documents; and,
- **Support national procurement of WHO-recommended, affordable, quality-assured medicines.**

ACTIONS TAKEN (1): MEDICINES REMOVED FROM GDF CATALOG

No longer recommended by WHO:

- Ofloxacin 200mg*
- Ofloxacin 400mg*
- Clarithromycin 250mg*
- Clarithromycin 500mg*
- Ethambutol/Isoniazid 400mg/150mg
- Isoniazid/Rifampicin 150mg/150mg

*Some NTPs were still using; TA provided to phase out



ACTIONS TAKEN (2): 24 SUBMISSIONS to 2019 WHO EML

7 Additions:

- Bedaquiline 100mg (to EML for children)
- Cycloserine 125mg mini-cap
- Ethambutol 100mg dispersible tablet
- Ethionamide 125mg dispersible tablet
- Levofloxacin 100mg dispersible tablet
- Linezolid 150mg dispersible tablet
- Moxifloxacin 100mg dispersible tablet

4 Deletions:

- Capreomycin 500mg
- Capreomycin 1000mg
- Kanamycin 500mg
- Kanamycin 1000mg

13 Changes/New Indications:

- Amox/Clav 125mg/31.25mg/5ml
- Amox/Clav 250mg/62.5mg/5mL
- Amox/Clav 250mg/125mg
- Amox/Clav 500mg/125mg
- Amox/Clav 875mg/125mg
- Clofazimine 50mg
- Clofazimine 100mg
- Delamanid 50mg
- Imipenem/cilastatin 250mg/250mg
- Imipenem/cilastatin 500mg/500mg
- Meropenem 500mg
- Meropenem 1000mg
- Rifabutin 150mg

Thanks to WHO GTBP for Efforts on EML Submissions;
Thanks to WHO EMP for Flexibility & Collaboration on EML Submissions

ACTIONS TAKEN (3): PRIORITY MEDICINES ADDED TO GLOBAL FUND EXPERT REVIEW PANEL EXPRESSION OF INTEREST

Expedited Review Under New Global Fund Ad-Hoc ERP Process

Prioritized Medicines:

- Pediatric Fixed-Dose Combination Medicines for DS-TB (RH, RHZ)
 - Rifampicin/Isoniazid 75mg/50mg dispersible approved Jul-2018 (Lupin)
- Clofazimine 50mg and Clofazimine 100mg
 - Clofazimine 50mg & 100mg approved Aug-2018 (Macleods); 2-year shelf life approved Jan-2019
 - Clofazimine 100mg approved Jan-2019 (Dong-A); 2-year shelf life
 - Now have 3 quality-assured clofazimine suppliers – just in time for new WHO DR-TB guidelines!

Thanks to Global Fund ERP & WHO Prequal for Efforts to Prioritize & Expedite Reviews for Critical Medicines

ACTIONS TO BE TAKEN, NEXT STEPS

Within TB

- Establish system across WHO, GF, GDF to communicate changes & react, accordingly
- Include additional information: EML for Children, Global Fund List of Health Products, other?
- Assess PQ EOI submissions for medicines no longer WHO recommended (km, cm, PAS)
- Identify opportunities to further consolidate market
- Explore development of pediatric TB formulary
- Submit recommendations for 2019 ERP EOI prioritization; expedite review
- Identify & push for development of missing medicines & formulations (based upon current guidelines)
- Identify & plan for missing medicines & formulations (based upon ongoing research)

Outside TB

- Interest within WHO to replicate dashboard for other diseases, conditions

COLLABORATIVE APPROACH, IN LOCKSTEP WITH SUSTAINABLE DEVELOPMENT GOALS

SDG 3: Ensure healthy lives and promote well-being for all at all ages.

SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development.



Thank You to Major Contributors & Collaborators



- Ramon Herrero Crespo
- Brian Kaiser
- Brenda Waning



Sourcing & Supply Chain:

- Philippe Francois
- Amelie Darmon
- Alain Prat



Global TB Programme:

- Karin Weyer
- Fuad Mirzayev
- Ernesto Jaramillo
- Malgosia Grzemska
- Annemieke Brands

Essential Medicines:

- Sue Hill
- Lorenzo Moja

Prequalification Programme:

- Emer Cooke
- Deus Mubangizi

USAID

- Cheri Vincent
- Thomas Chiang